Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1997 May;41(5):1166–1167. doi: 10.1128/aac.41.5.1166

Characterization of a mutation in the parE gene that confers fluoroquinolone resistance in Streptococcus pneumoniae.

B Perichon 1, J Tankovic 1, P Courvalin 1
PMCID: PMC163872  PMID: 9145891

Abstract

We report a mutation in the parE genes of two in vitro mutants of Streptococcus pneumoniae responsible for low-level resistance to fluoroquinolones. Sequential acquisition of mutations in parE and gyrA leads to higher levels of resistance. This confirms that topoisomerase IV is the primary target of fluoroquinolones in S. pneumoniae.

Full Text

The Full Text of this article is available as a PDF (190.5 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bernard Louis, Nguyen Van Jean-Claude, Mainardi Jean-Luc. In Vivo Selection of Streptococcus pneumoniae, Resistant to Quinolones, Including Sparfloxin. Clin Microbiol Infect. 1995 Sep;1(1):60–61. doi: 10.1111/j.1469-0691.1995.tb00027.x. [DOI] [PubMed] [Google Scholar]
  2. Breines D. M., Ouabdesselam S., Ng E. Y., Tankovic J., Shah S., Soussy C. J., Hooper D. C. Quinolone resistance locus nfxD of Escherichia coli is a mutant allele of the parE gene encoding a subunit of topoisomerase IV. Antimicrob Agents Chemother. 1997 Jan;41(1):175–179. doi: 10.1128/aac.41.1.175. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Ferrero L., Cameron B., Crouzet J. Analysis of gyrA and grlA mutations in stepwise-selected ciprofloxacin-resistant mutants of Staphylococcus aureus. Antimicrob Agents Chemother. 1995 Jul;39(7):1554–1558. doi: 10.1128/aac.39.7.1554. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Ferrero L., Cameron B., Manse B., Lagneaux D., Crouzet J., Famechon A., Blanche F. Cloning and primary structure of Staphylococcus aureus DNA topoisomerase IV: a primary target of fluoroquinolones. Mol Microbiol. 1994 Aug;13(4):641–653. doi: 10.1111/j.1365-2958.1994.tb00458.x. [DOI] [PubMed] [Google Scholar]
  5. Gensberg K., Jin Y. F., Piddock L. J. A novel gyrB mutation in a fluoroquinolone-resistant clinical isolate of Salmonella typhimurium. FEMS Microbiol Lett. 1995 Oct 1;132(1-2):57–60. doi: 10.1111/j.1574-6968.1995.tb07810.x. [DOI] [PubMed] [Google Scholar]
  6. Gootz T. D., Zaniewski R., Haskell S., Schmieder B., Tankovic J., Girard D., Courvalin P., Polzer R. J. Activity of the new fluoroquinolone trovafloxacin (CP-99,219) against DNA gyrase and topoisomerase IV mutants of Streptococcus pneumoniae selected in vitro. Antimicrob Agents Chemother. 1996 Dec;40(12):2691–2697. doi: 10.1128/aac.40.12.2691. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Ito H., Yoshida H., Bogaki-Shonai M., Niga T., Hattori H., Nakamura S. Quinolone resistance mutations in the DNA gyrase gyrA and gyrB genes of Staphylococcus aureus. Antimicrob Agents Chemother. 1994 Sep;38(9):2014–2023. doi: 10.1128/aac.38.9.2014. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Muñoz R., De La Campa A. G. ParC subunit of DNA topoisomerase IV of Streptococcus pneumoniae is a primary target of fluoroquinolones and cooperates with DNA gyrase A subunit in forming resistance phenotype. Antimicrob Agents Chemother. 1996 Oct;40(10):2252–2257. doi: 10.1128/aac.40.10.2252. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Pan X. S., Ambler J., Mehtar S., Fisher L. M. Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae. Antimicrob Agents Chemother. 1996 Oct;40(10):2321–2326. doi: 10.1128/aac.40.10.2321. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Pan X. S., Fisher L. M. Cloning and characterization of the parC and parE genes of Streptococcus pneumoniae encoding DNA topoisomerase IV: role in fluoroquinolone resistance. J Bacteriol. 1996 Jul;178(14):4060–4069. doi: 10.1128/jb.178.14.4060-4069.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Stein D. C., Danaher R. J., Cook T. M. Characterization of a gyrB mutation responsible for low-level nalidixic acid resistance in Neisseria gonorrhoeae. Antimicrob Agents Chemother. 1991 Apr;35(4):622–626. doi: 10.1128/aac.35.4.622. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Tankovic J., Perichon B., Duval J., Courvalin P. Contribution of mutations in gyrA and parC genes to fluoroquinolone resistance of mutants of Streptococcus pneumoniae obtained in vivo and in vitro. Antimicrob Agents Chemother. 1996 Nov;40(11):2505–2510. doi: 10.1128/aac.40.11.2505. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Yoshida H., Bogaki M., Nakamura M., Yamanaka L. M., Nakamura S. Quinolone resistance-determining region in the DNA gyrase gyrB gene of Escherichia coli. Antimicrob Agents Chemother. 1991 Aug;35(8):1647–1650. doi: 10.1128/aac.35.8.1647. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES